Solventum Q3 2026 Earnings: ERP Cutover Weighs on Sales as EPS Outlook Rises
Solventum reported Q3 2026 revenue of $1.949 billion, down 7.0% year over year, driven by ERP-related order timing and divestitures. Adjusted diluted EPS declined 3.6% to $1.45, while gross margins expanded due to portfolio optimization and savings programs. Health Information Systems delivered strong growth, offsetting notable organic declines in Dental Solutions and Infection Prevention. Management raised its full-year adjusted EPS guidance to $7.20–$7.30 and expects organic growth toward the high end of its range, while affirming free cash flow targets of $200–$300 million despite ongoing restructuring costs and negative year-to-date cash flow.
Solventum (NYSE: SOLV) reported Q3 2026 revenue of $1.949 billion, down 7.0% year over year, while GAAP diluted EPS fell to $(0.07) from $7.22 and adjusted diluted EPS declined 3.6% to $1.45. Organic sales decreased 2.8% as the reversal of orders placed early ahead of an ERP cutover reduced growth by 630 basis points, while quarterly operating and free cash flow improved.
Core Financial Results
The reported sales decline was wider than the organic decrease because divestitures, primarily the September 2025 sale of the Purification and Filtration business, reduced growth by 4.5 percentage points. Currency added 0.3 percentage points.
GAAP earnings faced a difficult comparison with the prior-year $1.518 billion business-sale gain and were also reduced by current restructuring and separation costs. The adjusted results showed a narrower decline, with adjusted operating margin contracting 70 basis points.
| Metric | Q3 2026 | Q3 2025 | Year-Over-Year Change |
|---|---|---|---|
| Revenue | $1,949 million | $2,096 million | -7.0% |
| Gross profit / GAAP gross margin | $1,062 million / 54.5% | $1,135 million / 54.2% | About -6.4% / +30 bps |
| Operating income / GAAP margin | $68 million / 3.5% | $1,690 million / 80.6% | -$1,622 million / -7,710 bps |
| Adjusted operating income / margin | $387 million / 19.9% | $431 million / 20.6% | About -10.2% / -70 bps |
| Net income (loss) | $(12) million | $1,266 million | -100.9% |
| GAAP diluted EPS | $(0.07) | $7.22 | -101.0% |
| Adjusted diluted EPS | $1.45 | $1.50 | -3.6% |
| Operating cash flow / free cash flow | $177 million / $97 million | $75 million / $(22) million | +136.0% / +$119 million |
GAAP gross margin rose 30 basis points to 54.5%, while adjusted gross margin increased 130 basis points to 57.1%. Solventum attributed the improvement to portfolio optimization, favorable mix and savings programs, partly offset by inflation and tariffs.
Business and Segment Performance
Health Information Systems produced the strongest organic growth and expanded its operating margin. Advanced Wound Care’s reported increase was mainly acquisition-driven, while Infection Prevention and Surgical Solutions and Dental Solutions recorded the largest organic declines.
| Business | Q3 Sales | Reported Growth | Organic Growth | Operating Margin |
|---|---|---|---|---|
| Advanced Wound Care | $528 million | +8.9% | +1.5% | — |
| Infection Prevention and Surgical Solutions | $683 million | -5.3% | -5.7% | — |
| MedSurg total | $1,211 million | +0.4% | -2.8% | 16.0% vs. 16.8% |
| Dental Solutions | $317 million | -6.7% | -7.4% | 20.1% vs. 25.7% |
| Health Information Systems | $356 million | +3.3% | +4.4% | 41.7% vs. 38.8% |
Advanced Wound Care benefited from a 7.2-percentage-point acquisition contribution, primarily reflecting the Acera acquisition, compared with organic growth of 1.5%. Health Information Systems’ organic sales rose 4.4%, and its operating margin expanded 290 basis points to 41.7%.
Dental Solutions moved in the opposite direction: organic sales declined 7.4%, and operating margin contracted 560 basis points to 20.1%. MedSurg’s overall margin decreased 80 basis points, reflecting the weakness in its Infection Prevention and Surgical Solutions business.
The divested Purification and Filtration business contributed $128 million of sales in Q3 2025 but none in the current quarter, materially affecting the reported company-level comparison.
Profitability, Cash Flow and Balance Sheet
The gap between GAAP and adjusted earnings remained substantial. Solventum excluded $90 million of acquisition-related amortization, $50 million of restructuring costs, $157 million of 3M separation-related costs, and smaller litigation and transaction-related items from adjusted operating income. Selling, general and administrative expenses increased 4.2% to $813 million, primarily because of higher restructuring-related operating costs.
Quarterly cash generation improved, with operating cash flow reaching $177 million and free cash flow turning positive at $97 million. Management said an IEEPA tariff refund helped the result. For the first nine months, however, operating cash flow declined to $215 million from $274 million, while free cash flow remained negative at $(32) million versus $(42) million a year earlier.
At September 30, cash and equivalents were $451 million, down from $878 million at the end of 2025. Accounts receivable increased to $1.364 billion from $1.034 billion, while inventories rose to $1.102 billion from $1.066 billion. Solventum also spent $403 million on treasury stock during the first nine months; total current and long-term debt remained around $5.1 billion.
ERP Order Timing Hit Sales and Adjusted Margin, While Gross Margin Expanded
The main operating issue was the reversal of Q2 advance orders placed before the Q3 ERP cutover. Solventum quantified the effect at 630 basis points of organic growth, more than the quarter’s 2.8% organic decline, and also identified the ordering shift as the primary reason adjusted operating margin fell 70 basis points.
At the same time, both GAAP and adjusted gross margins increased because portfolio actions, mix and savings offset part of the inflation and tariff pressure. This combination indicates that lower order volume and transition timing affected operating leverage even as product-level profitability improved. Solventum said its ERP cutovers were complete and that it had exited approximately 90% of its 3M transition service agreements.
Full-Year Guidance
Solventum raised its adjusted EPS outlook and now expects organic growth toward the high end of its existing range. It maintained its free cash flow guidance despite negative free cash flow through the first nine months.
| Metric | Latest FY2026 Guidance | Update |
|---|---|---|
| Organic sales growth | Toward the high end of +2.5% to +3.0% | Outlook raised toward the high end |
| Organic growth excluding SKU exits | Toward the high end of +3.5% to +4.0% | Excludes an approximately 100-basis-point SKU exit impact |
| Adjusted diluted EPS | $7.20 to $7.30 | Raised from $7.10 to $7.20 |
| Free cash flow | $200 million to $300 million | Affirmed |
Based on free cash flow of $(32) million for the first nine months, Solventum would need to generate approximately $232 million to $332 million in Q4 to reach its full-year range.
Risks Investors Should Monitor
- Order normalization: Q3 organic sales fell 2.8% after advance orders shifted demand into Q2. The pace at which ordering normalizes will affect Solventum’s ability to finish near the high end of its full-year organic growth range.
- Segment weakness: Infection Prevention and Surgical Solutions and Dental Solutions posted organic declines of 5.7% and 7.4%, respectively, while Dental’s operating margin also contracted materially.
- Inflation and tariff pressure: These costs partly offset portfolio, mix and savings benefits. The quarter’s cash flow also benefited from a tariff refund, making underlying cash conversion an important follow-up measure.
- Restructuring and separation costs: These expenses contributed to negative GAAP EPS and a 3.5% GAAP operating margin, despite a 19.9% adjusted margin.
- Full-year cash flow execution: Free cash flow remained negative for the first nine months, leaving a sizable Q4 contribution necessary to achieve the affirmed annual target.
Summary
Solventum’s Q3 sales decline largely reflected ERP-related order timing and the prior divestiture, while adjusted EPS and operating margin decreased more modestly. Gross margin expansion, positive quarterly free cash flow and stronger Health Information Systems performance provided offsets, but weakness in Dental and Infection Prevention remained notable. The next priorities are order normalization after the ERP cutover, conversion of improved margins into cash flow, and delivery of the raised EPS and reaffirmed free cash flow outlooks.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.